• About us
• Contact

Advertisement

Product › Details

AIDS drug_o

	Next higher product group	virostatic agent

Record changed: 2023-07-10

Advertisement

More documents for virostatic agent

• [1] Atriva Therapeutics GmbH. (11/9/22). "Press Release: Atriva Therapeutics Appoints Christian Pangratz as Chief Executive Officer, Implementing Planned Management Change". Tübingen, Frankfurt a.M. & Martinsried....
• [2] ReViral Ltd.. (4/7/22). "Press Release: Pfizer to Acquire ReViral and Its Respiratory Syncytial Virus Therapeutic Candidates". New York, NY, London & Research Triangle Park, NC....
• [3] Leyden Laboratories B.V.. (1/25/22). "Press Release: Leyden Labs Raises $200M in 2021 for a New Approach to Combat Viruses". Amsterdam & Boston, MA....
• [4] Pneumagen Ltd.. (1/19/22). "Press Release: Pneumagen Raises £3.8 million to Advance the Phase II Clinical Development of Neumifil, a Pan-antiviral, Intranasal Drug for the Prophylaxis and Treatment of Viral Respiratory Tract Infections (RTIs)". St Andrew...
• [5] ReViral Ltd.. (3/2/21). "Press Release: ReViral and LianBio Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Sisunatovir in China". London, et al.....
• [6] ReViral Ltd.. (8/25/20). "Press Release: ReViral Raises $44 Million in Series C Financing". London & Research Triangle Park, NC....
• [7] Exscientia Ltd.. (8/18/20). "Press Release: Europe’s Largest Initiative Launches to Accelerate Therapy Development for COVID-19 and Future Coronavirus Threats". Brussels....
• [8] GlaxoSmithKline plc. (1/8/20). "Press Release: Deborah Waterhouse, CEO of ViiV Healthcare, to Join GSK Corporate Executive Team (CET)". London....
• [9] GlaxoSmithKline plc. (7/3/19). "Press Release: ViiV Healthcare Receives EU Marketing Authorisation for Dovato (dolutegravir/lamivudine), a new once-daily, single-pill, two-drug regimen for the treatment of HIV-1 infection". London....
• [10] GlaxoSmithKline plc. (11/26/18). "Press Release: Juluca (dolutegravir/rilpivirine), the First Single Pill, 2-drug Regimen, for the Maintenance Treatment of HIV, Granted Marketing Approval by Japan Ministry of Health, Labour and Welfare". London....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.